SRZN SURROZEN INC

Surrozen To Report Fourth Quarter and Full Year 2022 Financial Results and Provide a Corporate Update on March 22, 2023

Surrozen To Report Fourth Quarter and Full Year 2022 Financial Results and Provide a Corporate Update on March 22, 2023

SOUTH SAN FRANCISCO, Calif., March 20, 2023 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), today announced that it will report fourth quarter and full year 2022 financial results and provide a corporate and pipeline progress report on Wednesday, March 22, 2023 after the close of the U.S. financial markets.   Company management will host a live audio webcast at 4:30 PM Eastern Time to discuss the corporate update and pipeline progress.

Interested parties may join the audio webcast via the Investor website at . To ensure a timely connection, it is recommended that individuals register at least 15 minutes prior to the start of the webcast.

About Surrozen

Surrozen is a clinical stage biotechnology company discovering and developing drug candidates to selectively modulate the Wnt pathway. Surrozen is developing tissue-specific antibodies designed to engage the body’s existing biological repair mechanisms with a current focus on inflammatory bowel, severe liver, and eye diseases. For more information, please visit surrozen.com.

Investor Contact:



EN
20/03/2023

Underlying

SRZNSURROZEN INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on SURROZEN INC

 PRESS RELEASE
Free
SRZN SURROZEN INC

Surrozen to Present at Upcoming Healthcare Investor Conference

Surrozen to Present at Upcoming Healthcare Investor Conference SOUTH SAN FRANCISCO, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- (“Surrozen” or the “Company”) (Nasdaq: SRZN), a biotechnology company pioneering targeted therapeutics to harness the power of Wnt signaling to address the underlying drivers of disease in sight-threatening ophthalmic conditions, today announced that Company management will present at an upcoming healthcare investor conference. TD Cowen 46th Annual Healthcare Conference on Wednesday, March 4, 2026 Fireside Chat at 1:10 PM Eastern Time / 10:10 AM Pacific Time In...

February 25, 2026 1 EN
 PRESS RELEASE
Free
SRZN SURROZEN INC

Surrozen Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Surrozen Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) SOUTH SAN FRANCISCO, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a biotechnology company pioneering targeted therapeutics to harness the power of Wnt signaling to address the underlying drivers of disease in sight-threatening ophthalmic conditions, today announced that on February 17, 2026, Surrozen granted a non-statutory stock option for an aggregate of 3,070 shares of Surrozen common stock to a recently hired non-executive employee as an inducement material ...

February 23, 2026 1 EN
 PRESS RELEASE
Free
SRZN SURROZEN INC

Surrozen to Present at Upcoming Healthcare Investor Conference

Surrozen to Present at Upcoming Healthcare Investor Conference SOUTH SAN FRANCISCO, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- (“Surrozen” or the “Company”) (Nasdaq: SRZN), a biotechnology company pioneering targeted therapeutics to harness the power of Wnt signaling to address the underlying drivers of disease in sight-threatening ophthalmic conditions, today announced that Company management will present at an upcoming healthcare investor conference. Guggenheim Emerging Outlook: Biotech Summit 2026 on Thursday, February 12, 2026 Presentation at 1:30 PM Eastern Time / 10:30 AM Pacific ...

February 5, 2026 1 EN
 PRESS RELEASE
Free
SRZN SURROZEN INC

Surrozen to Present at Upcoming Healthcare Investor Conferences

Surrozen to Present at Upcoming Healthcare Investor Conferences SOUTH SAN FRANCISCO, Calif., Nov. 25, 2025 (GLOBE NEWSWIRE) -- (“Surrozen” or the “Company”) (Nasdaq: SRZN), a biotechnology company pioneering targeted therapeutics that selectively modulate the Wnt pathway, with a focus on severe eye diseases, today announced that Company management will present at two upcoming healthcare investor conferences. 37th Annual Piper Sandler Healthcare Conference on December 2, 2025Surrozen Fireside Discussion at 6:30 AM Pacific Time/9:30 AM Eastern Time 8th Annual Evercore Healthcare Conferen...

November 25, 2025 1 EN
 PRESS RELEASE
Free
SRZN SURROZEN INC

Surrozen Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Surrozen Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) SOUTH SAN FRANCISCO, Calif., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a biotechnology company pioneering targeted therapeutics that selectively modulate the Wnt pathway, with a focus on severe eye diseases, today announced that on November 6, 2025, Surrozen granted inducement stock option awards covering an aggregate of 50,000 shares of Surrozen common stock to the newly appointed Chief Financial Officer, Andrew P. Maleki, as an inducement material to acceptance of ...

November 12, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch